Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifamycin SV-MMX in IBS-D
NCT03099785Phase 2Completed
- Sponsor
- Cosmo Pharmaceuticals
- Start
- Dec 2017
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of rifamycin SV-MMX in Irritable bowel syndrome with diarrhea (IBS-D), sponsored by Cosmo Pharmaceuticals. Started Dec 2017; status: completed.
02
Drugs
rifamycin SV-MMX
03
Conditions
Irritable bowel syndrome with diarrhea (IBS-D)
Beyond the preview
Go deeper on NCT03099785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03099785.